Investing.com - Amgen (NASDAQ: AMGN) reported first quarter EPS of $3.98, $0.16 better than the analyst estimate of $3.82. Revenue for the quarter came in at $6.1B versus the consensus estimate of $6.12B.
Guidance
Amgen sees Q2 2023 EPS of $17.60-$18.70 versus the analyst consensus of $17.72.
Amgen sees Q2 2023 revenue of $26.20B-$27.30B versus the analyst consensus of $26.70B.
Amgen sees FY 2023 EPS of $17.40-$18.60 versus the analyst consensus of $18.33.
Amgen sees FY 2023 revenue of $26.00B-$27.20B versus the analyst consensus of $27.30B.
Amgen's stock price closed at $240.34. It is down -5.25% in the last 3 months and up 0.93% in the last 12 months.
Amgen saw 1 positive EPS revisions and 10 negative EPS revisions in the last 90 days. See Amgen's stock price’s past reactions to earnings here.
According to InvestingPro, Amgen's Financial Health score is "good performance".
Check out Amgen's recent earnings performance, and Amgen's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar